The agreement pairs the iLet automated insulin delivery system with the sensor designed to continuously monitor glucose and ketone levels.
This marks the third such integration for the Abbott dual sensor. The company already struck deals with Sequel Med Tech and Tandem Diabetes Care to integrate the sensor with their automated insulin delivery systems. Though not commercial yet, the sensor would be the first of its kind to hit the market.
iLet, Beta Bionics’ automated insulin delivery system, streamlines diabetes management by reducing the burden on patients and physicians. It received FDA clearance in May 2023. iLet users can “go bionic,” requiring no carb counting or insulin correction calculations. Then, iLet determines 100% of the insulin doses throughout the day. The only input required to get started is the user’s weight.
The iLet system currently already supports the Abbott FreeStyle Libre 3 Plus continuous glucose monitor (CGM). Abbott’s future sensor is built on the same form factor as the Libre 3 Plus system. Beta Bionics says the integration further extends the collaboration between companies.
“This integration holds great promise for further enhancing real-time decision-making support for people living with diabetes,” said Sean Saint, president and CEO of Beta Bionics. “As the benchmark in automated insulin delivery systems, the iLet will naturally integrate with Abbott’s future dual glucose-ketone sensor as soon as it becomes commercially available.”
Beta Bionics continues to make waves in 2025 following its $234.6 million IPO in January. It has also reported growth, driven by the continued rollout of the iLet system.
